EndoStim added another tranche to its $16.5 million equity round, according to a regulatory filing, saying it’s added some $11.2 million to its coffers as it develops a pacemaker-like implant to treat gastro-esophageal reflux disease.
Intuitive Surgical
Robotic surgery: Mass. advisory sends Intuitive Surgical, Mako, Hansen shares down
Shares of the leading robotic surgery device makers all fell today, after a Massachusetts medical board issued an advisory to surgeons warning of possible risks with the cutting-edge technology.
Analysts defend Intuitive Surgical as docs defend robot-assisted surgery
Updated March 18, 2013, at 2:15 p.m. with a correction.
Analysts “surprised” at sudden Intuitive Surgical sell-off
Intuitive Surgical (NSDQ:ISRG) shares suffered a sudden sell-off today after the American Congress of Obstetricians & Gynecologists released a statement questioning some of the marketed benefits of robot-assisted surgery.
Intuitive Surgical: Adverse events are not on the rise
D+Vice Talk – March 7, 2013
Welcome to the latest edition of the MassDevice.com’s D+Vice Talk, our new webcast, in which we review medical device stories from the last week.
When it comes to robots, opinions run hot
FDA probes Intuitive Surgical on complication rates
The FDA is looking into complication rates for surgeries using Intuitive Surgical‘s (NSDQ:ISRG) da Vinci surgical robot, sending a survey to doctors who use the device.
Which medical device companies are the best to work for?
Johnson & Johnson (NYSE:JNJ) tops the charts as the best medical device company to work for according to Glassdoor.com, a database of anonymously posted information about salaries, interviews and jobs from current and former medical device industry employees.
Investors yawn at latest Citron jab, send Intuitive Surgical shares up
Investors, who sent shares of Intuitive Surgical (NSDQ:ISRG) down 10% the 1st time Citron Research issued a negative report on the medical device company, yawned today at a 3rd missive from the short seller.
ISRG shares were up slightly as of about 3:30 p.m. today to $561.07 apiece, despite Citron’s repeated assertion that the stock is headed for $300 per share.